Wednesday, February 10, 2010, 9:26AM AEST - The Australian Stockmarket opens in 34 minutes.
To create a watchlist or portfolio of shares, Register

CEL-SCI Corp. (CVM)

8:00AM AEST: 0.65 USD  Down 0.01 (1.52%)  
 MORE ON CVM 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 CEL-SCI CORP (AMEX:CVM) Delayed quote dataEdit
Last Trade:0.65 USD
Trade Time: 8:00AM AEST
Change:Down 0.01 (1.52%)
Prev Close:0.66
Open:0.67
Bid:N/A
Ask:N/A
1y Target Est:1.00
Day's Range:0.64 - 0.67
52wk Range:0.14 - 2.10
Volume:1,198,506
Avg Vol (3m):3,324,490
Market Cap:132.25M
P/E (ttm):N/A
EPS (ttm):-0.09
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add CVM to Portfolio   Download Data

 HEADLINES 
CEL SCI CORP Financials
EDGAR Online Financials (Sun, Feb 7)
CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
PR Newswire (Thu, Feb 4)
CEL SCI CORP Files SEC form 10-Q/A, Quarterly Report
EDGAR Online (Mon, Feb 1)
CEL SCI CORP Files SEC form 10-Q/A, Quarterly Report
EDGAR Online (Sat, Jan 30)
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corp.
Marketwire (Tue, Jan 26)
CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
PR Newswire (Sat, Jan 16)
Cel-Sci reports more cash, higher year-end losses
at bizjournals.com (Thu, Jan 14)
CEL SCI CORP Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review
EDGAR Online (Thu, Jan 14)
CEL-SCI Corporation Announces 2009 Financial Results
PR Newswire (Thu, Jan 14)
Cel-Sci manufacturing facility gets go ahead
at bizjournals.com (Tue, Jan 12)
More Headlines for CVM...

 ANALYST 
EPS Est (next year) (Jan-70) :N/A
EPS Est (in 2 years) (Jan-70) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. Its lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical ...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices